Teleflex Inc. designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company was founded in 1943 and is based in Wayne, Pennsylvania.
TFX Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Teleflex Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Teleflex Inc ranked in the 17th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Teleflex Inc, consider:
The company has produced more trailing twelve month cash flow than 61.74% of its sector Healthcare.
89% of the company's capital comes from equity, which is greater than 70.81% of stocks in our cash flow based forecasting set.
TFX's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 32.07% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as TFX, try AMPH, LGND, CNMD, LMNX, and ZBH.
Global Central Venous Catheter Market: The report provides a valuable source of insightful data for business strategists and competitive analysis of Central Venous Catheter Market. The study covers important knowledge that makes the analysis document a handy resource for managers,
WAYNE, Pa., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that new data published in the peer-reviewed journal, European Urology Focus, found that men treated with the Prostatic Urethral Lift (PUL) procedure (using the UroLift® System) showed preservation and some improvement of sexual function compared to men being treated with medication for benign prostatic hyperplasia (BPH). The comparative analysis “Prostatic Urethral Lift vs. Medical Therapy: Examining the Impact on Sexual Function in Men with BPH,” is the first study to longitudinally compare sexual function outcomes between major PUL studies1-4 and data from the Medical Therapy of Prostatic Symptoms (MTOPS) trial. Treatment-related changes in sexual function were reported by validated patien...
ReportsnReports.com the exclusive leading provider of market research reports published research report on “Global Cardiac Catheters Market Insights, Forecast to 2026”. The Global Cardiac Catheters Market Report 2020 is a professional and in-depth study on the current state of the Cardiac
DUBLIN, Jan. 8, 2021 /PRNewswire/ -- The "Central Venous Catheters (Drug Delivery Devices) - Global Market Analysis and Forecast Model (COVID-19 market impact)" report has been added to ResearchAndMarkets.com's offering. Central Venous Catheters (Drug Delivery Devices) - Global Market…
Market Overview Medical tubing market is expected to be growing at a growth rate of 9.30% in the forecast period of 2020 to 2027. Medical tubing market report analyses the growth, which is currently being growing due to the rising demand